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ABSTRACT
Human polynucleotide kinase/phosphatase (PNKP)
is a dual specificity 50-DNA kinase/30-DNA phosphat-
ase, with roles in base excision repair, DNA
single-strand break repair and non-homologous end
joining (NHEJ); yet precisely how PNKP functions in
the repair of DNA double strand breaks (DSBs)
remains unclear. We demonstrate that PNKP is
phosphorylated by the DNA-dependent protein kin-
ase (DNA-PK) and ataxia-telangiectasia mutated
(ATM) in vitro. The major phosphorylation site for
both kinases was serine 114, with serine 126 being
a minor site. Ionizing radiation (IR)-induced phos-
phorylation of cellular PNKP on S114 was ATM de-
pendent, whereas phosphorylation of PNKP on S126
required both ATM and DNA-PK. Inactivation of
DNA-PK and/or ATM led to reduced PNKP at DNA
damage sites in vivo. Cells expressing PNKP with
alanine or aspartic acid at serines 114 and 126
were modestly radiosensitive and IR enhanced the
association of PNKP with XRCC4 and DNA ligase IV;
however, this interaction was not affected by
mutation of PNKP phosphorylation sites. Purified
PNKP protein with mutation of serines 114 and 126
had decreased DNA kinase and DNA phosphatase
activities and reduced affinity for DNA in vitro.
Together, our results reveal that IR-induced phos-
phorylation of PNKP by ATM and DNA-PK regulates
PNKP function at DSBs.
INTRODUCTION
Exposure of cells to ionizing radiation (IR) results in the
generation of complex forms of DNA damage, including
damage to bases and cleavage of the DNA backbone to
form DNA single strand breaks (SSBs). Two SSBs on
opposite DNA strands approximately 6–10bp apart
results in the formation of a DNA double strand break
(DSB), which is considered the most lethal form of DNA
damage (1). The termini of IR-induced SSBs and DSBs
frequently contain 30-phosphate and 30-phosphoglycolate
groups (2) as well as 50-hydroxyls (3,4) that must be
restored to 30-hydroxyls and 50-phosphates before the
DNA ends can be ligated. A key enzyme responsible for
restoring ligatable end groups to IR-induced DNA strand
breaks in mammalian cells is polynucleotide kinase/phos-
phatase (PNKP), a dual function enzyme with both
30-DNA phosphatase and 50-DNA kinase activities (5–8).
Cells lacking PNKP are sensitive to IR and other
DNA-damaging agents (9,10) and in humans PNKP
mutation is associated with microcephaly and seizures
(10). PNKP functions in multiple pathways for the
repair of IR-induced DNA damage, including base exci-
sion repair (BER), DNA SSB repair and non-homologous
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target (7,11,12).
NHEJ, the major pathway for the repair of IR-induced
DSBs in mammalian cells, requires Ku70/80, DNA-
dependent protein kinase catalytic subunit (DNA-PKcs),
Artemis, XRCC4 (X-ray cross complementing gene 4),
XLF (XRCC4-like factor) and DNA-ligase IV (13).
PNKP enhances DNA-PK-dependent rejoining of DNA
substratescontaining50-hydroxylsinvitro(14)andinteracts
with XRCC4 in both a phosphorylation-dependent (15) and
a phosphorylation-independent manner (16), providing
possible mechanisms to recruit PNKP to DSBs in vivo.
Moreover, knock-down of PNKP does not increase the
radiation sensitivity of MO59J cells (17), which lack
DNA-PKcs and have reduced levels of the related protein
kinase ataxia-telangiectasia mutated (ATM) (18,19), sug-
gesting that PNKP functions in the same pathway as
DNA-PK and/or ATM. However, precisely how PNKP
functions in the repair of IR-induced DSBs is unknown.
Here, we show that both DNA-PK and ATM phos-
phorylate PNKP in vitro. The major site, serine 114
(S114), is an SQ site located in a ﬂexible linker region
that separates the amino-terminal forkhead-associated
(FHA) domain from the catalytic DNA phosphatase
and DNA kinase domains of PNKP (20,21). A second
SQ site, serine 126 (S126) is also phosphorylated in vitro
by DNA-PK, but to a lesser extent. Using phosphospeciﬁc
antibodies and metabolic labeling, we show that both
S114 and S126 are phosphorylated in vivo in response to
IR. IR-induced phosphorylation of S114 in vivo was ATM
dependent, whereas phosphorylation of S126 was reduced
by inhibition of ATM and/or DNA-PKcs. Cells express-
ing PNKP in which serines 114 and 126 were mutated to
alanine (to ablate phosphorylation) or aspartic acid (to
mimic phosphorylation) were modestly radiation sensitive.
Furthermore, inhibition of DNA-PKcs and/or ATM
reduced the amount of PNKP detected at DNA damage
sites in vivo, suggesting that phosphorylation by ATM
and/or DNA-PK regulates PNKP retention or turnover
at DSBs. To explore further the effects of DNA-PK and
ATM on PNKP function, we examined the effects of mu-
tation of S114 and S126 to alanine or aspartic acid on the
biochemical properties of PNKP. Mutation of S114 and
S126 reduced PNKP kinase and phosphatase activities as
well as the afﬁnity of PNKP for dsDNA. Together, our
studies suggest that phosphorylation of the ﬂexible linker
region of PNKP by ATM and/or DNA-PK regulates
PNKP catalytic activity, its interaction with DNA and
turnover and/or retention at sites of DNA damage.
MATERIALS AND METHODS
Cloning and puriﬁcation of PNKP in bacteria
His-PNKP was expressed as described previously (8). To
generate glutathione S transferase (GST)-tagged PNKP, a
vector expressing full-length human PNKP with a
C-terminal V5 tag (pcDNA3.1-PNK-V5), generously
provided by Dr D. Durocher (University of Toronto) (15),
was used as a template to amplify full-length human PNKP
(GeneBank accession number: AF125807.1) from HeLa
cells using primers 50-BamH1 and 30-XhoI (see
Supplementary Data for primer sequences). The PCR
product was cloned into the pGEX-6P-1 vector (GE
Healthcare) at BamH1/Xho1 restriction sites to produce
an N-terminal GST fusion protein. DNA sequences were
veriﬁed by the University of Calgary DNA Sequencing
Facility. GST-PNKP was expressed and puriﬁed in
Escherichia coli BL21-DE3 as described previously for
XLF (22). Where indicated, the GST tag was removed
using PreScission Protease (GE Healthcare) according to
the manufacturer’s instructions.
In vitro DNA-PK phosphorylation assays
DNA-PKcs and Ku were puriﬁed from the nuclear salt
wash of unirradiated HeLa cells or from human placenta
as described previously (23,24). Unless otherwise indi-
cated, phosphorylation reactions were carried out as desc-
ribed previously (22) and contained 1mg puriﬁed,
bacterially expressed PNKP in a ﬁnal volume of 20ml.
To calculate the stoichiometry of in vitro phosphorylation,
reactions were carried out with 0.25mM ATP containing
 1mCurie of
32P-g-ATP. Radioactively labeled bands were
excised from Coomassie blue-stained SDS–PAGE gels and
radioactivity was determined by Cerenkov counting. The
stoichiometry of phosphorylation was calculated from
32P-g-ATP (in cpm/pmol ATP) and expressed as pmol of
phosphate incorporated per pmol protein.
Identiﬁcation of in vitro PNKP phosphorylation sites
Puriﬁed His-PNKP (0.5mg) was incubated with DNA-
PKcs (0.3mg) and Ku (0.1mg) and phosphorylated
in vitro as described previously (25). Phosphoamino acid
analysis and identiﬁcation of phosphopeptides by mass
spectrometry and radiochemical sequencing/Edman deg-
radation was also carried out as described previously (25).
Generation of phosphorylation site mutations in GST-
PNKP and PNKP-V5
Serine to alanine mutations at serines 114 and 126 (S114A
and S126A, respectively) were generated by site-directed
mutagenesis from the pGEX-6P-1-PNKP-wt plasmid
using methods described previously (22) and primers
S114A and S126A (see Supplementary Data for primer
sequences). The double mutant (S114A-S126A) was
generated using pGEX-6P-1-PNKP-S126A vector as
template with the S114A primer. Alanine to aspartic acid
mutations were generated as above using primers A114D
and A126D (see Supplementary Data for details). The
double mutant was generated using the pGEX-6P-1-
PNKP-A114D vector as template with the A126D
primer. The same primers were used to generate serine to
alanine single and double mutations in the pcDNA3.1-V5
vector for mammalian expression (see below).
Generation of phosphospeciﬁc antibodies
A phosphospeciﬁc antibody recognizing S114 of PNKP
was raised in sheep against the phospho-peptide:
RTPESQPDTP, which corresponds to residues 110–119
of human PNKP. The phosphorylated serine is shown in
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and BSA and afﬁnity puriﬁed as described previously
(25). An antibody to S126 was raised in rabbits to the
phospho-peptide GTPLVSQDEK, which corresponds to
residues 121–130 of human PNKP. Phosphospeciﬁc
antibodies were puriﬁed as described previously (25).
Cell culture and irradiation
HeLa cells were grown in Dulbecco’s Modiﬁed Eagle
Medium (DMEM) containing 5% Hyclone III fetal
bovine serum, containing 50U/ml of penicillin and
50mg/ml of streptomycin, and maintained at 37 C under
an atmosphere of 5% CO2. BT/C3ABR cells were main-
tained in RPMI media plus 10% Hyclone III fetal bovine
serum with antibiotics as described above. Where
indicated, irradiation was carried out using a GammaCell
1000
137Cs source (MDS Nordion, Canada) as described
previously (22). Cells were pretreated withthe ATM inhibi-
tor KU55933 (26) and/or the DNA-PK inhibitor NU7441
(27) at the concentrations indicated prior to irradiation.
In vitro ATM phosphorylation assays
ATM-proﬁcient, human lymphoblastoid cells BT/C3ABR
cells were irradiated with 10 Gy IR and whole cell deter-
gent lysis extracts were prepared 30min after irradiation.
ATM was immunoprecipitated and assayed as described
previously (28,29). Where indicated, in vitro kinase reac-
tions contained 500nM KU55933 (26) to inhibit ATM
kinase activity.
Transient transfection
PNKP-V5 was transfected into HeLa cells using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s recommended conditions, except that half the
amount of DNA and one-third the amount of transfection
reagent was used. Unless otherwise indicated, cells were
harvested 24h post-transfection.
Stable expression of shRNA-resistant HA-tagged PNKP
in the A549-derived PNKP shRNA knockdown cell line,
Clone 13
A549 cells containing stable shRNA knock down of
PNKP (clone 13) were described previously (9) and were
maintained in DMEM/F12 media with 10% Hyclone III
fetal bovine serum, 350mg/ml G418, penicillin and strepto-
mycin as above. To generate shRNA-resistant wt-PNKP,
the bases shown in bold type in the shRNA target
sequence (1392-1411: AGAGATGACGGACTCCTCT)
were mutated using Quick Change II kit (Stratagene), to
yield the sequence AGAAATGACCGATTCCTCT,
which did not result in any changes in the amino acid
sequence of PNKP. The cDNA (in mammalian expression
vector pIRESpuro3, Clontech) was transfected into clone
13 cells using Lipofectamine 2000 as above. After 24h,
cells were placed under G418 (0.4mg/ml) and puromycin
(0.8mg/ml) selection for 14 days. Individual colonies were
expanded in selection media and the resultant cell lines
were tested for the expression of HA-PNKP by immuno-
blotting with an antibody to HA (Sigma) following the
manufacturer’s recommendations. Cells re-expressing
shRNA-resistant PNKP were maintained in medium con-
taining 0.4mg/ml G418 and 0.8mg/ml puromycin in
addition to penicillin and streptomycin as above.
Immunoprecipitation
For immunoprecipitation from HeLa cells transiently
transfected with PNKP-V5 vectors, cells were lysed in
NP-40 containing buffer (NETN) [150 mM NaCl,
0.2mM EDTA, 50mM Tris–HCl, pH 7.5, 1% (v/v)
NP-40] containing 1mM microcystin-LR, 0.2mM
phenylmethylsulfonyl ﬂuoride, 2mg/ml aprotinin, 2mg/ml
leupeptin and 2mg/ml pepstatin A, with sonication. Protein
concentrations were determined using the Detergent
Compatible Protein Assay (BioRad) using BSA as a
standard. PNKP was immunoprecipitated from 1mg of
total protein using anti-V5 IgG (Serotec) and Protein
G-Sepharose beads (GE Healthcare). Precipitates were
washed six times with 1ml NETN buffer (containing
protease inhibitors) per wash, and then analyzed by
SDS–PAGE and immunoblot.
For immunoprecipitation from PNKP-depleted cells
stably transfected with shRNA-resistant PNKP, cells
were harvested and lysed as above, but immunopre-
cipitated with antibodies to HA (Sigma). Where indicated,
immunoblots were also probed with antibodies to XRCC4
(Serotec), DNA ligase IV (Serotec), Mre11 (Novus), ATM
(a gift from Dr Martin Lavin, Queensland Institute of
Medical Research), Ku80 (in house) and DNA-PKcs (in
house) as indicated. Blots were developed with ECL
reagent (GE Healthcare), exposed to X-ray ﬁlm (Fuji)
and quantiﬁed using ImageQuant (GE Healthcare). In
some experiments, immunoblots were imaged and
quantiﬁed using a Fujiﬁlm LAS-4000 Luminescent
Image Analyzer (Fujiﬁlm Corp., Tokyo).
Identiﬁcation of in vivo phosphorylation sites by mass
spectrometry
HeLa cells were transiently transfected with PNKP-V5
and PNKP was immunoprecipitated from 10mg of total
protein. Immunoprecipitates were washed six times with
1ml of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) buffer (50mM HEPES, pH 7.5, 40mM
NaCl, 2mM EDTA) containing 0.5M LiCl, 1% (v/v)
Triton X-100 plus protease inhibitors as above, followed
by a further 10 washes with 1ml of PBS per wash.
Phosphopeptides were identiﬁed by WEMB Inc. as
described previously (22). Where indicated, beads were
treated with 200U lambda phosphatase (NEB) and
incubated at 30 C for 30min prior to SDS–PAGE and
immunoblot.
Metabolic labeling
HeLa cells were transiently transfected with vectors ex-
pressing wild-type PNKP with a C-terminal V5 tag
(PNKP-V5), or PNKP-V5 containing serine to alanine
mutations at S114 or S114 plus S126 (PNKP-S114A-V5
and PNKP-S114A-S126A-V5, respectively) and incubated
in phosphate-free media for 2h. The medium was replaced
with fresh phosphate-free media supplemented with
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32P inorganic phosphate/ml media, and cells were
returned to the incubator for 1h. The cells were then lysed
in NETN buffer containing phosphatase and protease in-
hibitors and PNKP was immunoprecipitated from 1.5mg
total protein as described above and resolved by SDS–
PAGE. The gel was stained with Coomassie Brilliant
Blue (Bio-Rad) and exposed to X-ray ﬁlm (Fuji) for 36h
at  80 C.
Calculation of in vivo stoichiometry of phosphorylation
PNKP was phosphorylated in vitro using puriﬁed
DNA-PK as above but with non-radioactive ATP.
Known amounts of phosphorylated PNKP were run on
SDS–PAGE along with PNKP that had been immunopre-
cipitated from irradiated cells and immunoblots were de-
veloped with phospho-speciﬁc antibodies to serine 114 and
126 as described above. Phosphorylation of PNKP in vivo
was compared with phosphorylation of known amounts
of in vitro phosphorylated PNKP after normalization for
protein loading (total PNKP by western blot), stoichiom-
etry of phosphorylation in vitro from
32P-labeling experi-
ments (0.34–0.35pmol phosphate/pmol protein,
Supplementary Figure 1) and DNA-PK-mediated phos-
phorylation of serine 114 and 126 in vitro, by
phospho-speciﬁc antibody cross-reactivity.
Clonogenic survival assays
Cells were serially diluted and plated at various concen-
trations ranging from 1 10
2 to 7 10
2 cells/plate.
Twenty-four hours after plating, cells were irradiated
with 0, 2, 4 or 6 Gy IR and incubated at 37 C for 10–14
days. Colonies were stained with crystal violet and
counted on a Bantex 920A colony counter (American
Bantex Corp., Burlingame, CA, USA).
Two-photon laser microirradiation
Cells were grown in DMEM/F12 (50/50) plus 10% fetal
bovine serum on 35-mm glass bottom culture dishes
(MatTek Corp., Ashland, MA, USA). The following day,
cells were transfected with a DNA construct (PNKP cDNA
cloned into the pCMV6-AC-mRFP vector Origene,
Rockville,MD,USA)encodingforPNKP-mRFPexpression
underthecontroloftheCMVpromoter.Twenty-fourhours
after transfection, cells were incubated with Hoechst 33258
to a ﬁnal concentration of 2mg/ml for 20min and then fed
with fresh growth medium for 10min prior to
microirradiation. Where indicated, cells were incubated
with 10mM NU7441 and/or KU55933 for 2h prior to
microirradiation. For laser microirradiation, cells were
placed on a 37 C heated stage of a Zeiss LSM510 NLO
laser-scanning confocal microscope. Microirradiation was
carried out using a near infrared titanium sapphire laser. In
order to introduce damage within nuclei of individual cells,
a 1.2-mm wide region was pre-deﬁned and subsequently
microirradiated with 20 iterations of a 750-nm laser line at
10% power using a Plan-Neoﬂuar  40/1.3 NA oil immer-
sion objective. Fluorescence imaging of the mRFP moiety
was recorded using excitation with a 543-nm He–Ne laser
and a 559–634nm band-pass ﬁlter. mRFP-tagged PNKP
accumulation at the region of interest was compared with
a non-irradiated region, and the accumulation of PNKP at
sites of DNA damage was quantiﬁed as enrichment relative
to unirradiated regions. Cells with low expression levels of
PNKP-mRFP were selected and ﬂuorescence intensity at
regions of interest was quantiﬁed. The intensity was
normalized so that the total cell intensity remained
constant throughout the experiment. This compensates
for photobleaching during acquisition. Images were then
realigned using Image J software and subsequently ﬂuores-
cence signals of the exported Tiff images were quantiﬁed
using Metamorph software 6.0 (Molecular Devices,
Sunnyvale, CA, USA).
In vitro PNKP kinase and phosphatase assays
In vitro PNKP kinase assays were carried out as described
previously (16). Brieﬂy, reaction mixtures containing
kinase buffer [80 mM succinic acid (pH 5.5), 0.2nmol of
24 mer ssDNA substrate (HO 24: 50-GGCGCCCACCAC
CACTAGCTGGCC-30) (Integrated DNA Technology),
3.3pmol of
32P-ATP (Perkin-Elmer), 0.4nmol unlabeled
ATP, 10mM MgCl2 and 500ng of enzyme (ﬁnal volume
50ml)] were incubated at 37 C. From the reaction mixture,
4ml samples were taken at several incubation times up to
10min and mixed with 2ml of sequencing gel loading dye
(Fisher Scientiﬁc), boiled and run at 200V on a 12% poly-
acrylamide sequencing gel (Bio-Rad) containing 7M urea
(EMD). Gels were scanned on a Typhoon 9400 variable
mode imager (GE Healthcare) and the resulting bands
were quantiﬁed using Image Quant 5.2 software (GE
Healthcare).
For in vitro PNKP phosphatase assays, 50-radiolabeled
substrate was prepared by incubation at 37 C for 30s of
120pmol 30-phosphorylated 20-mer DNA oligonucleotide
(20P: 50-ATTACGAATGCCCACACCGC-30-phosphate)
(Integrated DNA Technology) with 30U of
phosphatase-free T4 phage polynucleotide kinase
(Roche) and 9.9pmol g
32P-ATP (Perkin Elmer), in
buffer A [50 mM Tris–HCl (pH 8.0), 10mM MgCl2,
0.1mM EDTA, 5mM dithiothreitol, 0.1mM spermidine]
in a total volume of 72ml. The sample was then heated at
95 C for 5min to inactivate the T4 phage PNKP. To
monitor phosphatase activity, 12ml of the resulting
32P
labeled substrate was mixed with 20ng of human PNKP
in buffer A (total volume 30ml) and incubated at room
temperature. Aliquots (4ml) were taken at 0, 0.5, 1, 2 and
5min intervals, mixed with 2ml sequencing gel loading dye
(Fisher Scientiﬁc), boiled and analyzed as above.
DNA binding assays
In vitro DNA binding assays were carried out by ﬂuores-
cence quenching in the presence of 45bp duplex DNA as
described previously (16).
RESULTS
DNA-PK and ATM phosphorylate PNKP predominantly
on serine 114 in vitro
Given that PNKP has been implicated in NHEJ and the
catalytic activity of DNA-PK is required for NHEJ (30),
Nucleic Acids Research, 2011,Vol.39, No. 21 9227we ﬁrst asked whether PNKP was an in vitro substrate for
DNA-PK. His-tagged PNKP was expressed in bacteria,
puriﬁed, then incubated with puriﬁed DNA-PKcs and
Ku and phosphorylated under standard assay conditions
(Figure 1A). The stoichiometry of phosphorylation was
 0.5 moles of phosphate per mole of PNKP (data not
shown). To identify in vitro DNA-PK phosphorylation
sites, phosphorylated His-tagged PNKP was extracted
from the gel pieces, and, after reduction and alkylation,
the protein was digested with trypsin and phosphopeptides
were identiﬁed using mass spectrometry. A single phos-
phopeptide was detected which corresponded to S114 in
the sequence TPESQPDTPPGTPLVSQDEK (the phos-
phorylated amino acid is shown in bold and underlined)
(Figure 1B and C).
To determine whether S114 represented a major in vitro
phosphorylation site, S114 was mutated to alanine
(PNKP-S114A) and the protein was again phosphorylated
by DNA-PK (Figure 2A). For these experiments, muta-
tions were generated in GST-tagged PNKP and the GST
tag was removed prior to phosphorylation. The stoichiom-
etry of phosphorylation of wt-PNKP ranged from 0.34 to
0.35pmol of phosphate per pmol PNKP (Supplementary
Figure S1). Bands corresponding to phosphorylated
PNKP were excised and quantiﬁed. PNKP in which
S114 was replaced by alanine (PNKP-S114A) was phos-
phorylated to 56 2% of wild-type (WT), conﬁrming
mass spectrometry results and indicating that S114 repre-
sents a major in vitro phosphorylation site (Figure 2A).
S114 is located in a ﬂexible linker region that connects
the FHA domain of PNKP to the catalytic domain (21).
Also present in this 35 amino acid linker is a second SQ
site, S126 (Figure 2B). To determine whether DNA-PK
also phosphorylated this residue in vitro, S126 was mutated
to alanine and the mutant protein (PNKP-S126A) was
incubated with DNA-PK under standard phosphorylation
conditions. Conversion of S126 to alanine decreased
DNA-PK mediated phosphorylation of PNKP to 89 
15% (Figure 2A), indicating that, under these conditions,
S126 represents only  10% of the total in vitro phosphor-
ylation by DNA-PK. Mutation of both S114 and S126
decreased phosphorylation by  50% (Figure 2A, lane
8), suggesting the presence of additional in vitro PNKP
phosphorylation sites, but these were not pursued further.
To determine whether S114 and S126 were also sub-
strates for ATM, ATM was immunoprecipitated from
irradiated human cells and incubated with puriﬁed
PNKP as substrate. Where indicated, reactions contained
the ATM inhibitor KU55933 (26). ATM also phosphory-
lated PNKP in vitro and again the major site was S114
(Figure 2C).
Serine 114 is a major in vivo PNKP phosphorylation site
To determine whether PNKP was phosphorylated at these
sites in vivo, HeLa cells were transiently transfected with a
vector encoding PNKP with a C-terminal V5 tag
(PNKP-V5) (a kind gift from Drs Durocher and Koch,
University of Toronto). Under these conditions, PNKP-
V5 was expressed  12-fold above endogenous PNKP
levels (Supplementary Figure 2) and was predominantly
Figure 1. Identiﬁcation of DNA-PK phosphorylation sites in PNKP.
(A) Puriﬁed His-tagged PNKP (0.5mg) was incubated with or without
DNA-PK (400ng), calf thymus DNA (10mg/ml) or 10mM wortmannin,
as indicated by the + or   symbols. The reaction was carried out at
30 C for 30min and stopped by boiling in SDS sample buffer. Proteins
were separated by electrophoresis on a 10% SDS polyacrylamide gel
stained with Coomassie blue, and dried for autoradiography. (B)
Puriﬁed PNKP, phosphorylated by DNA-PK, was separated by elec-
trophoresis on an SDS polyacrylamide gel and then digested with
trypsin as described in ‘Materials and methods’ section. The resulting
32P-labeled peptides were chromatographed on a Vydac 218TP54 C18
column (Separation Group, Hesperia, CA, USA) equilibrated in 0.1%
(v/v) triﬂuoroacetic acid in water. The column was developed with a
linear acetonitrile gradient (dashed diagonal line, right hand Y-axis) at
0.8ml/min, and fractions of 0.4ml were collected: >80% of the radio-
activity applied to the column was recovered in the fractions. (C)A n
aliquot of the major
32P-labeled peptide derived from phosphorylated
PNKP (Figure 1B) was covalently coupled to a Sequelon acrylamide
membrane and analyzed on an Applied Biosystems 476A sequenator.
32P radioactivity was measured after each cycle of Edman degradation.
In combination with MALDI-TOF MS, database searching
against predicted PNKP tryptic peptides and phosphoamino acid
analysis (data not shown) enabled the identiﬁcation of the site of phos-
phorylation in the peptide. The putative amino acid sequence of this
peptide, deduced from a combination of phosphoamino acid analysis,
MS and solid-phase sequencing, is indicated at the bottom of the
graph.
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(data not shown). PNKP was immunoprecipitated from
transiently transfected cells and phosphorylation sites
were identiﬁed by mass spectrometry as described in
‘Materials and Methods’. Both S114 and S126 were
detected as in vivo phosphorylation sites (Supplementary
Figure 3).
To determine whether S114 and S126 were major sites
of in vivo phosphorylation, HeLa cells were transiently
transfected with either wild-type PNKP (PNKP-V5), or
PNKP-V5 containing serine to alanine mutations at
serine 114 (PNKP-S114A-V5) or both serines 114 and
126 (PNKP-S114A-S126A-V5). Cells were then metabol-
ically labeled using
32P-labeled inorganic phosphate as
described in ‘Materials and methods’ section and PNKP
was immunoprecipitated using antibodies to V5, resolved
by SDS–PAGE, and exposed to X-ray ﬁlm. Metabolic
labeling conﬁrmed that PNKP is phosphorylated in vivo
under these conditions (Figure 2D). Mutation of S114 to
alanine reduced PNKP phosphorylation by  70%, while
mutation of S114 and S126 to alanine reduced phosphor-
ylation by a further 10–15% (Figure 2D). Technical
difﬁculties prevented us from exposing cells to IR during
these experiments and therefore the observed phosphoryl-
ation likely represents endogenous phosphorylation as
well as phosphorylation induced by DNA damage due
to incubation with
32P-inorganic phosphate.
PNKP is phosphorylated on serine 114 in an
ATM-dependent manner in vivo in response to IR
To further characterize the phosphorylation of PNKP
in vivo, we generated phospho-speciﬁc antibodies to phos-
phorylated S114 and S126. Both antibodies recognized
puriﬁed wt-PNKP in a phosphorylation–dependent
manner and were speciﬁc for their respective phosphoryl-
ation sites in vitro and in vivo (Supplementary Figure 4A
and B). HeLa cells were transiently transfected with
PNKP-V5 or PNKP-S114A-V5, then, after 24h, cells
were irradiated (2 Gy) and 30min later, PNKP was im-
munoprecipitated as described above. Immunoprecipitates
were either run directly on SDS–PAGE (Figure 3A, odd
numbered lanes) or incubated in the presence of lambda
phosphatase (ppase) prior to SDS–PAGE (Figure 3A,
even numbered lanes). After SDS–PAGE, immunoblots
were probed with either the phospho-speciﬁc antibody to
S114 (Ab: pSer-114) or an antibody to V5 (to detect total
transfected PNKP) (Figure 3A). The results conﬁrm that
PNKP is phosphorylated on S114 in vivo in response to
IR. Phosphorylation of S114 was detected at 0.5 Gy and
the amount of phosphorylation increased up to 10 Gy
(Figure 3B). Phosphorylation was detected as early as
30min and persisted up to 4h post IR (Figure 3C).
Given that both DNA-PK and ATM phosphorylate
S114 in vitro, we next asked whether phosphorylation of
PNKP on S114 required DNA-PK or ATM in vivo. Cells
were transfected with either vector alone, PNKP-V5, or
PNKP-S114A-V5 as described above, but prior to irradi-
ation, cells were pretreated with either the DNA-PK in-
hibitor NU7441 (27) or the ATM inhibitor KU55933 (26)
at doses experimentally determined to be speciﬁc for the
respective kinase (Supplementary Figure 5). Signiﬁcantly,
pre-treatment with the DNA-PK inhibitor NU7441 had
no effect on IR-induced phosphorylation of PNKP on
S114 (Figure 4A), while pre-treatment with the ATM
Figure 2. PNKP is phosphorylated on serines 114 and 126 in vitro and
in vivo. (A) Puriﬁed recombinant PNKP or PNKP containing serine to
alanine mutations at either serines 114, 126 or both was incubated with
puriﬁed DNA-PK either in the absence ( ) or presence (+) of ATP.
Reactions were stopped by the addition of SDS sample buffer and
samples were run on SDS–PAGE. The top panel shows the resulting
autoradiograph. The lower panel is the Coomassie blue-stained gel in
the region corresponding to PNKP. To calculate stoichiometry,
32P-labeled bands were excised from the gel and the amount of radio-
activity incorporated was determined by Cerenkov counting.
32P in-
corporation was normalized to total PNKP levels (determined by
Coomassie staining) and expressed as percent of wild-type. The experi-
ment was repeated three times and a representative result is shown.
Phosphorylation of PNKP mutants S114A, S126A and S114A/S126A
were 56 2%, 89 15% and 50 8%, relative to wild-type, respect-
ively. (B) Amino acid sequence of the linker region (amino acids 111–
140) between the FHA and catalytic domain of PNKP. Serines 114 and
126 are shown in bold. (C) ATM was immunoprecipitated from
irradiated human lymphoblastoid cells and immunoprecipitates were
incubated with either wt-PNKP or PNKP containing serine to
alanine mutations at serines 114 (S114A) and/or 126 (S126A) as
indicated. Where indicated (+), the ATM inhibitor KU55933 was
added to reactions prior to addition of ATP. The upper and lower
panels correspond to the resulting autoradiogram and Ponceau
red-stained nitrocellulose blot, respectively. (D) HeLa cells were trans-
fected with vector alone (v, lane 1), wt-PNKP-V5 (wt, lane 2),
PNKP-S114A-V5 (lane 3) or PNKP-S114A-S126A-V5 (lane 4). Cells
were labeled with
32P-inorganic phosphate, then PNKP was
immunoprecipitated and phosphorylation was determined by autoradi-
ography (top panel) and quantitation after normalization to total
PNKP levels (bottom panel). Quantitation as percent phosphorylation
compared with wt-PNKP is shown below the panel.
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(Figure 4B).
Although, these results eliminated a role for DNA-PK
under these experimental conditions, we considered it
possible that DNA-PK might play a role at higher doses
of IR or at longer times after irradiation. Indeed, we have
previously observed that IR-induced phosphorylation of
the PIKK target Artemis is largely ATM dependent at low
doses of IR (<2 Gy) and short times (<2h) after IR, while
at higher doses (10–20 Gy) and longer times (4h), phos-
phorylation becomes in part DNA-PK dependent (R. Ye,
S. Hiebert and S.P. Lees-Miller, unpublished data).
However, phosphorylation of PNKP on S114 remained
highly ATM dependent 4h post 20 Gy IR (Figure 4C).
We next examined phosphorylation of S126 in response
to IR. HeLa cells were transiently transfected with
PNKP-V5, pretreated with NU7441 or KU55933 then
irradiated with 10 Gy. Phosphorylation at S126 was also
IR inducible (Figure 4D, lane 3) and pre-incubation with
the ATM inhibitor KU55933 reduced phosphorylation by
 90% (Figure 4D, lane 4). However, pre-treatment with
the DNA-PK inhibitor reduced phosphorylation by
 65% (Figure 4D, lane 5), while pre-treatment with
both inhibitors abolished phosphorylation (Figure 4D,
lane 6). Thus, both ATM and DNA-PK contribute to
IR-induced phosphorylation of PNKP on S126.
The experiments described above were carried out
in cells that had been transiently transfected with
wt-PNKP. We have previously observed that transient
transfection can promote DNA-PK-dependent phosphor-
ylation of some substrates in the absence of additional
DNA damage (22). To eliminate any possible effects of
transient transfection, we examined PNKP phosphoryl-
ation in PNKP-depleted cells (clone 13) into which
shRNA-resistant HA-tagged wt-PNKP had been stably
introduced (see ‘Materials and methods’ section). In
these cells, PNKP was expressed at approximately 5-fold
higher levels than endogenous PNKP in the parental A549
cell line (Supplementary Figure S6A), and PNKP ex-
pression was predominantly nuclear (Supplementary
Figure S6B). Cells stably expressing wt-PNKP were
irradiated (10 Gy) and PNKP was immunoprecipitated
1, 4, 8, 16 and 24h later. Immunoprecipitates were run
on SDS–PAGE and immunoblots were analysed for phos-
phorylation at serine 114, serine 126 and total PNKP
(Figure 5A). As found for cells transiently transfected
with PNKP, IR induced phosphorylation of PNKP at
serines 114 and 126 within 1h. Interestingly, phosphoryl-
ation at both sites started to diminish by 4h post IR and
returned to close to background levels by 24h (Figure 5A
and B).
To estimate the stoichiometry of in vivo phosphoryl-
ation, known amounts of puriﬁed PNKP that had been
phosphorylated in vitro by DNA-PK were run on the same
gels (Figure 5A, lanes 7–9). The stoichiometry of phos-
phorylation at both sites at the time of maximum phos-
phorylation (1h) was  0.1pmol of phosphate/pmol of
protein indicating that  10% of the total PNKP is phos-
phorylated in response to DNA damage (Figure 5A and B).
To determine whether ATM or DNA-PK was respon-
sible for IR-induced phosphorylation in these cells, cells
were pre-incubated with either NU7441 or KU5593 or
both inhibitors together. As found for phosphorylation
of PNKP after transient transfection, PNKP phosphoryl-
ation at both S114 and S126 was virtually abolished by
pre-incubation with either the ATM inhibitor alone
or both the ATM and DNA-PK inhibitors together
(Figure 5C, lanes 3 and 5), while incubation with the
DNA-PK inhibitor alone reduced phosphorylation of
S126 by  70% (Figure 5C), consistent with phosphoryl-
ation of S114 being ATM dependent, while both ATM
and DNA-PK contribute to phosphorylation of S126.
Mutation of S114 and S126 to phospho-mutants or
phospho-mimics imparts modest radiosensitivity to cells
To further examine the effects of PNKP phosphorylation
on the cellular response to IR, shRNA-resistant PNKP
Figure 3. IR induces phosphorylation of PNKP on S114. (A) HeLa
cells were transfected with vector alone (v, lanes 1 and 2), wt-PNKP
(wt, lanes 3–6) or PNKP-S114A (S114A, lanes 7–10). Where indicated
(+), cells were irradiated with 2 Gy and after 0.5h, cells were lysed and
PNKP immunoprecipitated as described in ‘Materials and Methods’
section. Where indicated (even numbered lanes), samples were
incubated with lambda phosphatase (ppase) prior to SDS–PAGE.
Immunoblots were probed either with the phospho-speciﬁc antibody
to S114 (upper panel) or V5 (lower panel) for total PNKP protein.
(B) Cells were either untreated (u, lane 1), or transfected with vector
alone (v, lane 2), PNKP-S114A-V5 (lane 3) or wt-PNKP-V5 (lanes
4–10) as indicated. Cells were irradiated and harvested after 1h.
Samples in lanes 1–3 and 10 received 10 Gy; the sample in lane 4
was unirradiated; samples in lanes 5–9 received 0.25, 0.5, 1, 2, or 5
Gy as indicated. Immunoblots were probed for phosphorylation of
PNKP on S114 or total PNKP (V5) as indicated. (C) Cells were
either untreated (u, lane 1), or transfected with vector alone (v, lane
2), PNKP-S114A-V5 (lane 3) or wt-PNKP-V5 (lanes 4–10) as in (B).
Cells were either unirradiated (lane 4), or irradiated at 2 Gy and har-
vested after 4h (lanes 1–3 and 8) or after 0.5, 1 or 2h (lanes 5–7).
PNKP was immunoprecipitated and analyzed by SDS–PAGE and
immunoblot as described above.
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(PNKP-2A and PNKP-2D, respectively) was re-intro-
duced into the shRNA-depleted cell line (clone 13) and
stable cell lines were isolated. Sensitivity to IR was
determined using clonogenic/colony formation assays.
Cells lacking PNKP protein were radiosensitive as re-
ported previously (9) and stable expression of wt-PNKP
partially restored radioresistance (Figure 6A). However,
expression of PNKP in which both S114 and S126 had
either been ablated (PNKP-2A) or mutated to the
phospho-mimic aspartic acid (PNKP-2D) did not restore
radiation resistance and were as radiosensitive as the
PNKP-depleted cells (Figure 6B).
Mutation of S114 or S126 to a phospho-mutant or a
phospho-mimic does not alter the interaction of PNKP
with XRCC4
PNKP interacts with XRCC4, which in turn interacts with
DNA ligase IV (31), providing a possible mechanism for
recruitment of PNKP to DSBs in NHEJ. To test whether
phosphorylation might disrupt the interaction of PNKP
with XRCC4, cells stably expressing PNKP-WT,
PNKP-2A or PNKP-2D were irradiated, PNKP was
immunoprecipitated and immunoblots were probed for
the presence of XRCC4 and DNA ligase IV. Although
the total amount of immunoprecipitated PNKP
remained constant, the amount of XRCC4 and DNA
ligase IV that interacted with PNKP increased signiﬁ-
cantly after IR (Figure 7, lanes 4–9 and Supplementary
Figure S7). However, mutation of the two PNKP phos-
phorylation sites did not affect the IR-enhanced inter-
action of PNKP with XRCC4 and DNA-ligase IV
(Figure 7 and Supplementary Figure S7), suggesting that
the enhanced interaction of PNKP and XRCC4 after IR
does not require phosphorylation at these sites.
Immunoblots were also probed for the presence of
ATM, DNA-PKcs and Ku, but these proteins did not
co-immunoprecipitate with PNKP under these conditions
(Supplementary Figure S7).
PNKP recruitment to DSBs is impaired in cells deﬁcient
for DNA-PKcs and ATM
We have previously shown that depletion of PNKP in the
DNA-PKcs/ATM-defective cell line MO59J (18,19) does
not increase radiation sensitivity, suggesting an epistatic
relationship between PNKP and DNA-PKcs and/or ATM
(17). To explore further the relationship between PNKP,
DNA-PKcs and ATM, RFP-tagged PNKP was expressed
in MO59J cells or the DNA-PKcs/ATM proﬁcient cell line
MO59K (isolated from the same tumor specimen as
MO59J), and DNA damage was introduced using two-
photon laser microirradiation. PNKP was recruited to
sites of DNA damage rapidly (<1min) and with similar
kinetics in both MO59J and MO59K cells, suggesting that
DNA-PKcs and ATM are not required for actual recruit-
ment of PNKP to sites of DNA damage in vivo. However,
considerably less PNKP was recruited in MO59J cells, sug-
gesting that DNA-PKcs and/or ATM might play a role
in the retention of PNKP at sites of damage (Figure 8A
and B). To explore this possibility further, RFP-tagged
PNKP was expressed in HeLa cells and cells were
pre-treated with either KU55933, NU7441 or both inhibi-
tors together prior to laser microirradiation. Inhibition of
either DNA-PKcs or ATM or both together signiﬁcantly
Figure 4. IR-induced phosphorylation on serine 114 is ATM depend-
ent, while phosphorylation at serine 126 is both ATM and DNA-PK
dependent. (A) Cells were either untransfected (u, lane 1), or transfected
with vector (v, lane 2), PNKP-S114A-V5 (lane 3) or wt-PNKP-V5
(lanes 4–8). Twenty-four hours after transfection, cells were pretreated
with 10mM NU7441 (DNA-PK inhibitor) (lanes 1, 2, 3 and 7), DMSO
control (lane 4), 2mM NU7441 (lane 5) or 5mM NU7441 (lane 6) for
2h prior to irradiation (2 Gy, lanes 1–7). The sample in lane 8 was not
irradiated. Thirty minutes after irradiation, PNKP was immunopre-
cipitated and analyzed by western blot using the phospho-speciﬁc
antibody to S114 or V5 for total PNKP as above. (B) Cells were
pre-treated with the indicated concentrations of the ATM inhibitor
KU55933 for 2h, then irradiated (2 Gy) and analyzed exactly as
described above. PNKP was immunoprecipitated and observed by
western blotting with either the phospho-speciﬁc antibody to S114 or
V5 for total PNKP. As above, u and v represent untransfected (lane 1)
and vector (lane 2). S114A refers to the S114A mutant of PNKP (lane
3). (C) Cells were pre-treated with either 10mM NU7441 or 5mM
KU55933 and either unirradiated (lane 3) or irradiated at 20 Gy
(lanes 1, 2, 4–8) and harvested after 1h (lane 4) or 4h (lanes 1, 2,
5–8). PNKP was immunoprecipitated and analyzed by western
blotting with either the phosphospeciﬁc antibody to S114 or V5 for
total PNKP as above. (D) Cells were pre-treated with NU7441 and/
or KU55933 as in (C), then irradiated (10 Gy). PNKP was immunopre-
cipitated after 30min and analyzed by western blot as described, but
using a phospho-speciﬁc antibody to serine 126.
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induced sites of damage without altering the initial time
of recruitment (Figure 8C), suggesting that phosphoryl-
ation of PNKP by ATM and DNA-PK regulates the re-
tention or turnover of PNKP at DNA damage sites
in vivo.
Both ablation and mimicry of S114 and S126 reduce
PNKP activity in vitro
To investigate whether phosphorylation of PNKP on S114
and S126 might affect its biochemical properties, wild-type
(wt) PNKP or PNKP-containing alanine (to ablate phos-
phorylation) or aspartic acid (to mimic phosphorylation)
at serines 114 and 126 were expressed and puriﬁed from
E. coli and PNKP DNA kinase and DNA phosphatase
activities were determined as described in ‘Materials and
Methods’ section. Mutation of either S114 or S126 to A
had no effect on PNKP kinase activity (data not shown).
Similarly, mutation of S126 to D (phosphomimic) had no
effect on PNKP kinase activity, whereas mutation of S114
to D (S114D) or mutation of both S114 and S126 to D
(PNKP-114D-126D) reduced by  40% the ability of PNKP
to phosphorylate the 50-end of ssDNA (Figure 9A). Thus,
replacement of S114 with a phosphomimic negatively
affects PNKP kinase activity, suggesting that phosphoryl-
ation at S114 may regulate PNKP kinase activity in vitro
(see also ‘Discussion’ section). Mutation of S114 to D also
reduced PNKP phosphatase activity toward 30-phosphory-
lated ssDNA by  25% (Figure 9B, triangles). Mutation of
S126 to D had a greater effect on PNKP phosphatase
activity, reducing activity by 50% (Figure 9B, inverted
Figure 5. IR-induced phosphorylation of PNKP at S114 is transient
and ATM dependent while phosphorylation of S126 is transient and
requires both DNA-PK and ATM. (A) PNKP knockdown cells (C13)
stably expressing shRNA-resistant wt-PNKP were unirradiated (lane 1)
or irradiated (10 Gy) and harvested 1, 4, 8, 16 or 24h post IR. PNKP
was immunoprecipitated and immunoblots were probed for phosphor-
ylation at S114, S126 or total PNKP as indicated. (B) Quantitation of
immunoblots shown in (A). (C) PNKP knockdown cells (C13) stably
expressing shRNA-resistant wt-PNKP were pre-treated with 10mM
KU55933, 10mM NU7441 or both for 60min prior to treatment with
10 Gy IR. Cells were harvested after 60min and PNKP was
immunoprecipitated using an antibody to HA, resolved by SDS–
PAGE and blotted for phosphoserine 114, phosphoserine 126 or total
PNKP as indicated.
Figure 6. Mutation of S114 and S126 to either alanine or aspartic acid
induces a radiosensitive phenotype. (A) A549 cells (triangles), A549
cells with stable downregulation of PNKP (clone 13 cells, squares)
and cells containing stably re-expressed shRNA-resistant wt-HA-
PNKP (circles) were plated in triplicate and allowed to adhere for
24h. Cells were then treated with 0, 2, 4, or 6 Gy IR and incubated
for 10–14 days. Colonies were stained with crystal violet and counted.
The surviving fraction and the SEM were calculated. Data are repre-
sentative of three separate experiments. (B) Cells containing stably
re-expressed wt-HA-PNKP (circles), HA-PNKP-S114A-S126A (2A, tri-
angles), HA-PNKP-S114D-S126D (2D, inverted triangles) or a stably
introduced vector control (squares) were plated and analyzed as above.
9232 Nucleic Acids Research, 2011,Vol.39, No. 21triangles), while mutation of both S114 and S126 to A or
D reduced PNKP phosphatase activity by 25 and 50%,
respectively (Figure 9B). Thus, mutations that result in
either ablation or phosphomimicry of S114 and S126
negatively affect PNKP phosphatase activity, with re-
placement of both S114 and S126 by aspartic acid
having the most signiﬁcant effect.
We also asked whether mutation of serines 114 and 126
affected the ability of PNKP to interact with dsDNA.
Wt-PNKP bound DNA with a Kd of 0.55 0.05mM
(Figure 9C). Kd values for PNKP with S114A, S114D,
S126A and S126D mutations were 0.75 0.05,
0.9 0.05, 1.2 0.1 and 1.10 0.1mM, respectively (data
not shown). PNKP with mutation of both 114 and 126 to
either A or D had Kd values of 1.0 0.1 and 1.8 0.1mM,
respectively (Figure 9C). Thus, ablation or phospho-
mimicry of PNKP phosphorylation sites adversely affected
the afﬁnity of PNKP for DNA, with the double phos-
phomimic mutation (PNKP-S114D-S126D) having the
strongest effect on DNA binding.
DISCUSSION
PNKP interacts with XRCC4 (15) and enhances DNA-
PK-dependent rejoining of NHEJ substrates containing
50-hydroxyl groups in vitro (14). Moreover, PNKP-
deﬁcient cells are radiosensitive (9). These observations,
combined with its enzymatic properties, have suggested
a role for PNKP in NHEJ; yet precisely how PNKP func-
tions in DSB repair has not been determined. Here we
show that both DNA-PK and ATM phosphorylate
PNKP on SQ sites located in a 35 amino acid ﬂexible
linker region, which tethers the FHA domain to the
catalytic phosphatase and kinase domains (20). This
linker, which corresponds to amino acids 111–145 of
human PNKP, was disordered in the crystal structure
(21) and its function is unknown. The major in vitro
PNKP phosphorylation site for both DNA-PK and
ATM was S114, with S126 being a minor site. Our
results also suggest that DNA-PK may phosphorylate
additional sites in PNKP, but these were not identiﬁed
in this study (Figure 2A).
In vivo, IR-induced phosphorylation of PNKP on S114
was largely ATM dependent, suggesting that ATM may
directly phosphorylate S114 in vivo in response to IR. S126
was also phosphorylated in vivo in response to IR and with
similar kinetics to S114. Using the highly selective ATM
and DNA-PK inhibitors KU55933 and NU7441, we show
that the major S126 kinase was again ATM; however,
NU7441 also reduced PNKP S126 phosphorylation, sug-
gesting that both ATM and DNA-PK contribute to phos-
phorylation at this site in irradiated cells. Indeed, our
results suggest that ATM kinase activity may be
required for DNA-PK to phosphorylate PNKP at S126
(Figures 4C and 5C), suggesting cross-talk between ATM
and DNA-PKcs in response to IR.
The stoichiometry of phosphorylation of PNKP on
S114 and 126 in response to IR was  0.1pmol phos-
phate/pmol protein, or  10% (Figure 5). We have cal-
culated that a similar fraction of DNA-PKcs is
phosphorylated in response to IR (32), consistent with
only a fraction of the total population of NHEJ proteins
recruited to and phosphorylated at DSBs. IR-induced
phosphorylation of PNKP at both S114 and S126 was
rapid, reaching a maximum within 1h but transient, di-
minishing to 50% within  5h and to pre-irradiation levels
by 24h (Figure 5B). Since the total amount of PNKP was
unchanged, these data suggest that IR-induced phosphor-
ylation of PNKP is regulated by protein phosphatases.
Recent phosphoproteomics studies have also identiﬁed
serines 114 and 126 as IR- (33,34) and UV- (35) inducible
sites of phosphorylation. Our study conﬁrms and extends
these results, showing that phosphorylation at S114 is
ATM dependent after IR while both ATM and DNA-
PK contribute to phosphorylation of S126. Metabolic
labeling experiments revealed that mutation of both
serine 114 and 126 to alanine reduced phosphorylation
by only 85%, suggesting that PNKP is phosphorylated
on additional sites in vivo. Our preliminary mass spec-
trometry analysis provided evidence for phosphorylation
of T39 and T111 (data not shown) and T111 was inde-
pendently identiﬁed as a UV-inducible phosphorylation
site in a proteomics screen (35). Moreover, T118 and
T122 have also been identiﬁed as DNA damage-inducible
in vivo phosphorylation sites in phosphoproteomics screens
(33–35) (see also PhosphoSitePlus, www.phosphosite.
org, search term PNKP); thus, remarkably, all ﬁve of
the phosphorylatable amino acids (Ser or Thr) in the 35
amino acid ﬂexible linker of PNKP (Figure 2B), can be
phosphorylated in response to DNA damage in vivo.I ti s
interesting to note that the related protein, Aprataxin-
PNKP-like factor (APLF), which has also been implicated
in NHEJ, is phosphorylated by ATM on an SQ site located
between the FHA module and the carboxy-terminal
Figure 7. IR enhances the interaction between PNKP, XRCC4 and
DNA ligase IV. C13 PNKP knockdown cells stably re-expressing
vector (vec, lanes 1 and 2), shRNA-resistant wt HA-PNKP (lanes 3
and 4), HA-PNKP-S114A-S126A (2A, lanes 5 and 6) or
HA-PNKP-S14D-S126D (2D, lanes 7 and 8) were either unirradiated
( ) or irradiated 10 Gy (+) and harvested after 60min. HA-PNKP was
immunoprecipitated and resolved by SDS–PAGE as described above.
Immunoblots were probed for HA (for PNKP), XRCC4 or DNA
Ligase IV as indicated. Whole cell extract of 50mg (input) was also
analyzed for XRCC4 and DNA ligase IV levels (bottom two panels).
See also Supplementary Figure S7.
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that the ﬂexible linker region plays important roles in
regulating the function of the PNKP family of proteins.
We show that PNKP is recruited to sites of microlaser-
induced DNA damage rapidly (within 20s), consistent
with its role in the rapid repair of modiﬁed DNA
termini (Figure 8). Initial recruitment of PNKP to sites
of DNA damage did not require DNA-PKcs or ATM;
however, the amount of PNKP at DNA damage sites
was reduced in cells lacking DNA-PKcs and ATM
protein or in which their activity had been inhibited, sug-
gesting that phosphorylation of PNKP by ATM and
Figure 8. Recruitment of PNKP to sites of DNA damage induced by two-photon laser microirradiation is impaired in DNA-PK/ATM-deﬁcient
cells. (A) MO59K and MO59J glioma cells transiently expressing PNKP-mRFP were subjected to laser microirradiation (as described in ‘Materials
and Methods’ section). Recruitment kinetics of PNKP-mRFP at laser-induced DNA damage sites in individual cells was monitored in real time. (B)
The amount of the ﬂuorescently tagged protein at tracks of DNA damage was quantiﬁed (n=11 cells for each data set; error bars represent SEM).
The red line represents MO59K and the blue line represents MO59J cells. (C) HeLa cells expressing PNKP-mRFP were incubated with DMSO (red
squares), the ATM inhibitor KU55933, 10mM (green diamonds), the DNA-PK inhibitor NU7741, 10mM (yellow squares) or both inhibitors
together, 10mM (blue triangles) for 2h prior to microirradiation. Samples were quantiﬁed as in (A) and (B).
9234 Nucleic Acids Research, 2011,Vol.39, No. 21DNA-PK could play a role in the retention or turnover of
PNKP at sites of DNA damage.
Consistent with previous reports, shRNA PNKP-
depleted cells were modestly radiosensitive (9). shRNA
PNKP-depleted cells stably expressing shRNA-resistant
wt-PNKP partially restored radiation resistance, while ex-
pression of PNKP in which serines 114 and 126 had been
replaced by alanine did not. Although this result is con-
sistent with phosphorylation of PNKP at S114 and S126
being required for survival after IR, cells expressing
PNKP with aspartic acid substitutions (PNKP-2D) were
as radiation sensitive as PNKP-depleted cells. It is possible
that aspartic acid at these sites may be a poor phospho-
mimic or that amino acid substitution within the linker
region might affect PNKP function, perhaps by altering its
conformation. Alternatively, the ﬁnding that IR-induced
phosphorylation of PNKP is transient (Figure 5) suggests
that PNKP phosphorylation may play a regulatory role
required for the correct coordination of PNKP function in
DNA repair. It is therefore possible that constitutive phos-
phorylation, as mimicked by the PNKP-2D mutant, could
have deleterious consequences for the cell, preventing
complementation.
Our experiments also reveal that IR signiﬁcantly en-
hances the interaction of XRCC4 and DNA ligase IV
with PNKP. However, interaction of XRCC4 with
PNKP-2A and PNKP-2D was also enhanced after IR,
indicating that phosphorylation at these sites is not re-
quired for the enhanced interaction of PNKP and
XRCC4 after IR, and the mechanism for this enhanced
interaction is under investigation. Our results do not ex-
clude the possibility that PNKP phosphorylation at these
sites may regulate the interaction with other proteins after
DNA damage and this possibility is also under
investigation.
PNKP protein containing mutations at S114 and S126
was also assayed for the effects on PNKP kinase, phos-
phatase and DNA binding activities in vitro. Although
mutation of S114 or S126 to aspartic acid had little
effect on the initial rate of PNKP kinase activity,
mutation of S114 to aspartic acid either in the context of
PNKP-S114D or PNKP-2D, resulted in a clear plateau in
PNKP activity at later times (Figure 9A). This suggests
that the S114D mutation, which mimics phosphorylation
at S114, may increase product inhibition of PNKP kinase
activity, which in turn suggests that phosphorylation at
S114 may increase the afﬁnity of PNKP for 50-phosphory-
lated termini. We speculate that this increased afﬁnity
could serve to protect the exposed ends of a partially
repaired DSB from degradation, analogous to the
‘passing the baton’ model for BER (37). This effect was
speciﬁc for S114, suggesting that phosphorylation at S114
and S126 might have distinct effects on PNKP kinase
activity. In contrast, mutation of either S114 or S126 to
D, as well as mutation of both sites to either alanine or
aspartic acid (PNKP-2A and PNKP-2D, respectively),
reduced phosphatase activity suggesting different effects
of phosphorylation on PNKP kinase and phosphatase
activities.
It is also interesting to note that mutation of both the
identiﬁed phosphorylation sites to aspartic acid (PNKP-
2D) had signiﬁcant effects on multiple PNKP activities
in vitro, reducing the ability of PNKP to either remove a
phosphate group from the 30-end of the DNA substrate or
to add a phosphate group to the 50-OH termini of DNA
and reducing the afﬁnity of PNKP for DNA approximate-
ly 4-fold. Although the linker region does not appear to be
in close contact with the two active sites of PNKP (21), it
is possible that the mutation of the two serines to aspartic
acid residues causes sufﬁcient conformational change
to the protein to reduce both of its enzymatic activities.
On the other hand, ablation of the two phosphorylation
sites by mutation to alanine reduced PNKP phosphatase
Figure 9. Effect of mutation of PNKP S114 and S126 on in vitro
PNKP kinase, phosphatase and DNA binding activities. Wild-type
(wt) PNKP or PNKP with serine to aspartic acid (phosphomimic) or
alanine (to ablate phosphorylation) mutations at positions 114 and/or
126 were expressed and puriﬁed from E. coli and assayed for DNA
kinase (A) or DNA phosphatase (B) activity as described in ‘Materials
and Methods’ section. Circles, wt PNKP; diamonds, PNKP-S114D;
triangles, S126D; inverted triangles, S114D–S126D (2D). The concen-
trations of PNKP and DNA in the kinase assays (A) were 0.175 and
4mM, respectively, and in the phosphatase assays (B), 11.6nM and
0.667mM, respectively. (C) wt PNKP and PNKP containing S to A
or S to D mutations at serines 114 and/or 126 were prepared and
puriﬁed from E. coli as in (A) and (B) and assayed for binding to
45bp duplex DNA by ﬂuorescence quenching as described in
‘Materials and Methods’ section. Results for wt (circles), 2A
(squares) and 2D (inverted triangles) are shown.
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mutation of serine to alanine can be considered more
benign than mutation to the negatively charged aspartic
acid, any conformational change may only affect the
phosphatase domain of PNKP to which the linker is
directly attached, rather than the more distal kinase
domain.
Together, our results suggest that PNKP is recruited to
sites of DNA damage presumably through its interactions
with XRCC4 and that IR-induced phosphorylation of
PNKP by ATM and/or DNA-PK may promote the reten-
tion of PNKP at sites of DNA damage. In addition, our
in vitro experiments suggest that modiﬁcation of the
ﬂexible linker region of PNKP has signiﬁcant effects on
PNKP activity, and that phosphorylation of the linker
may be important for PNKP function.
While this article was under review, Shiloh and col-
leagues reported ATM-dependent phosphorylation of
PNKP on S114 and S126 in response to the radiomimetic,
neocarzinostatin (NCS) (38). The authors showed that
PNKP-depleted cells were modestly sensitive to DNA-
damaging agents and that re-introduction of PNKP
lacking S114 and/or S126 only partially restored resistance
to X-rays and NCS. Cells unable to undergo phosphoryl-
ation at S114 or S126 were also defective in DSB repair
and showed impaired phosphatase activity in cell extracts.
Our results conﬁrm a role for ATM in phosphorylation of
PNKP at S114 and extend these studies to show that
DNA-PK is also involved in the phosphorylation of
S126. Our study also reveals that phosphorylation of
both sites after IR is transient, suggesting regulation by
protein phosphatases. The ability of phosphorylation
mutants to restore resistance to DNA damage was
modest in the study by Segal-Raz et al. (38) and the dif-
ference between our results and theirs may reﬂect differ-
ences in the cell lines used. Together, our studies reveal
new roles for ATM and DNA-PK in the regulation of
PNKP function in human cells.
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